Last reviewed · How we verify

Difelikefalin Injection — Competitive Intelligence Brief

Difelikefalin Injection (Difelikefalin Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinin B1 receptor agonist. Area: Nephrology.

phase 3 Kinin B1 receptor agonist Kinin B1 receptor (B1R) Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Difelikefalin Injection (Difelikefalin Injection) — Vifor Fresenius Medical Care Renal Pharma. Difelikefalin is a selective agonist of the peripheral kinin B1 receptor that reduces pruritus by modulating inflammatory pathways in patients with chronic kidney disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Difelikefalin Injection TARGET Difelikefalin Injection Vifor Fresenius Medical Care Renal Pharma phase 3 Kinin B1 receptor agonist Kinin B1 receptor (B1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinin B1 receptor agonist class)

  1. Vifor Fresenius Medical Care Renal Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Difelikefalin Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/difelikefalin-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: